Dr. Juan Granada discusses how sustained drug release sets the Eluvia Stent System apart from other vascular stents

Designed for Better Patient Outcomes

See how the Ranger Drug Coated Balloon leverages proven
and safe Boston Scientific technologies for the SFA and help
improve patients’ lives.

Jay Kokate
Director, Research and Development - Boston Scientific Corporation

Ranger is a next generation DCB supported by Level 1 evidence.

Image

STERLING PLATFORM

Ranger is available on the 0.018" Sterling balloon catheter platform which contributes to its ease of use and deliverability. Ranger has a proprietary loading tool to ensure coating integrity. Ranger has one of the broadest size matrix including new 120, 150 and 200 mm lengths

Explore Product Design

TRANSPAX™ COATING TECHNOLOGY

Ranger's TransPax™ Techonolgy consists of Paclitaxel + Citrate ester (Excipient) for best in class coating integrity, making Ranger more efficient DCB. Ranger is able to use approximately half the drug load that is used in IN.PACT DCB

Dr. Juan Granada discusses how sustained drug release sets the Eluvia Stent System apart from other vascular stents

Eluvia and Ranger are the lowest drug dose density devices among all peripheral paclitaxel-based technologies.

 

 

Data from Eluvia, Lutonix, Stellarex, Ranger, Zilver PTX and IN.PACT DFUs.

 
 

Ranger uses a unique combination of low drug dose with a proprietary excipient for efficient, local drug-delivery



*Comparitive tissue levels up to 60 days of a standard dose paclitaxel-coated balloon (PCB) (In.Pact) versus a lower-dose balloon (Ranger) in the superficial femoral artery territory of the swine. Dashed line represents the comparitive data with the Lutonix PCB (11). DCB = drug-coated balloon. 

**JACC Gongora C. et. al. , Impact of Paclitaxel Dose on Tissue Pharmacokinetics and Vascular Healing: A Comparative Drug-Coated Balloon Study in the Familial Hypercholesterolemic Swine Model of Superficial Femoral In-Stent Restenosis. JACC Cardiovasc Interv. 2015 Jul;8(8):1115-23 Preclinical results may not necessarily be indicative of clinical performance.

Design for Better Patient Outcomes
 
Dr. Juan Granada discusses how sustained drug release sets the Eluvia Stent System apart from other vascular stents

Total Drug Lost to Tracking, Inflation & Deflation



*Bench Testing performed by Boston Scientific.  Results not necessarily indicative of clinical performance. Data on File Boston Scientific.

 
Video showing how the Eluvia Drug-Eluting Vascular Stent was designed for better patient outcomes

DCB Design & platform


The Ranger Drug Coated balloon is indicated for Percutaneous Transluminal Angioplasty (PTA) in the peripheral vasculature. It has been designed to provide consistent and predictable drug delivery through efficient drug transfer, and a strong coating integrity
Sign Up Today

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Explore Resources

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Top